Skip to main content

Table 2 Haematological and nonhaematological toxicity

From: Phase I study of miriplatin combined with transarterial chemotherapy using CDDP powder in patients with hepatocellular carcinoma

 

Level 1

Level 2

Level 3

n = 3

n = 3

n = 3

Grade

Hematological toxicity (grade)

1

2

3

4

1

2

3

4

1

2

3

4

White blood cell decreased

0

1

0

0

0

0

1

0

0

0

0

0

Neutrophil count decreased

0

1

0

0

0

0

1

0

0

0

0

0

Platelet count decreased

0

1

0

0

0

0

0

0

2

0

0

0

Anemia

0

1

0

0

0

0

0

0

0

0

0

0

Nonhematological toxicity (grade)

1

2

3

4

1

2

3

4

1

2

3

4

AST increased

0

1

0

0

1

1

0

0

0

1

0

0

ALT increased

0

1

0

0

1

1

0

0

0

1

0

0

Blood bilirubin increased

0

0

0

0

1

0

0

0

1

0

0

0

INR increased

0

0

0

0

0

0

0

0

0

0

0

0

Hypoalbuminemia

0

2

0

0

0

1

0

0

1

0

0

0

Creatinine increased

0

0

0

0

0

0

0

0

1

0

0

0

Anorexia

0

0

0

0

0

0

0

0

1

0

0

0

Nausea

0

0

0

0

0

0

0

0

0

0

0

0

Vomiting

0

0

0

0

0

0

0

0

0

0

0

0

Fever

1

0

0

0

1

0

0

0

2

0

0

0

Diarrhea

0

0

0

0

0

0

0

0

0

0

0

0

Fatigue

0

0

0

0

0

0

0

0

1

0

0

0

Alopecia

0

0

0

0

0

0

0

0

0

0

0

0

Urticaria

0

0

0

0

0

0

0

0

0

0

0

0

Abdominal pain

0

0

0

0

0

0

0

0

0

0

0

0

  1. National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 was applied to evaluate toxicity.